Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review

J.M. Jacquet; P. Begue; E. Grimprel; P. Reinert; S. Sandbu; S.A. Silfverdal; G. Faldella; T. Nolan; S. Lambert; Peter Richmond; H. Marchall; D. Roberton; L. Schuerman

doi:10.1016/j.vaccine.2005.12.009

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review

J.M. Jacquet, P. Begue, E. Grimprel, P. Reinert, S. Sandbu, S.A. Silfverdal, G. Faldella, T. Nolan, S. Lambert, Peter Richmond, H. Marchall, D. Roberton, L. Schuerman

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming. Over 99% vaccines developed antibody levels considered to be protective to diphtheria, tetanus and poliovirus, and > 95% mounted a response to acellular pertussis antigens. Rectal temperature > 39.5 degrees C was observed in at most 3.2% of vaccinees. Swelling > 50 mm occurred in 24% of DTPa-primed compared to 5.5% of DTPw-primed children. Large swelling involving the entire upper arm (extending to involve the elbow joint) was reported for up to 1.2% of DTPa-primed subjects, which is consistent with literature reports for other DTPa vaccines. (c) 2005 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	2440-2448
Journal	Vaccine
Volume	24
Issue number	13
DOIs	https://doi.org/10.1016/j.vaccine.2005.12.009
Publication status	Published - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.12.009

Cite this

Jacquet, J. M., Begue, P., Grimprel, E., Reinert, P., Sandbu, S., Silfverdal, S. A., Faldella, G., Nolan, T., Lambert, S., Richmond, P., Marchall, H., Roberton, D., & Schuerman, L. (2006). Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review. Vaccine, 24(13), 2440-2448. https://doi.org/10.1016/j.vaccine.2005.12.009

@article{4ae1bb0c2ef9451a9fff1563b8863eb0,

title = "Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review",

abstract = "A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming. Over 99% vaccines developed antibody levels considered to be protective to diphtheria, tetanus and poliovirus, and > 95% mounted a response to acellular pertussis antigens. Rectal temperature > 39.5 degrees C was observed in at most 3.2% of vaccinees. Swelling > 50 mm occurred in 24% of DTPa-primed compared to 5.5% of DTPw-primed children. Large swelling involving the entire upper arm (extending to involve the elbow joint) was reported for up to 1.2% of DTPa-primed subjects, which is consistent with literature reports for other DTPa vaccines. (c) 2005 Elsevier Ltd. All rights reserved.",

author = "J.M. Jacquet and P. Begue and E. Grimprel and P. Reinert and S. Sandbu and S.A. Silfverdal and G. Faldella and T. Nolan and S. Lambert and Peter Richmond and H. Marchall and D. Roberton and L. Schuerman",

year = "2006",

doi = "10.1016/j.vaccine.2005.12.009",

language = "English",

volume = "24",

pages = "2440--2448",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "13",

}

Jacquet, JM, Begue, P, Grimprel, E, Reinert, P, Sandbu, S, Silfverdal, SA, Faldella, G, Nolan, T, Lambert, S, Richmond, P, Marchall, H, Roberton, D & Schuerman, L 2006, 'Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review', Vaccine, vol. 24, no. 13, pp. 2440-2448. https://doi.org/10.1016/j.vaccine.2005.12.009

TY - JOUR

T1 - Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review

AU - Jacquet, J.M.

AU - Begue, P.

AU - Grimprel, E.

AU - Reinert, P.

AU - Sandbu, S.

AU - Silfverdal, S.A.

AU - Faldella, G.

AU - Nolan, T.

AU - Lambert, S.

AU - Richmond, Peter

AU - Marchall, H.

AU - Roberton, D.

AU - Schuerman, L.

PY - 2006

Y1 - 2006

N2 - A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming. Over 99% vaccines developed antibody levels considered to be protective to diphtheria, tetanus and poliovirus, and > 95% mounted a response to acellular pertussis antigens. Rectal temperature > 39.5 degrees C was observed in at most 3.2% of vaccinees. Swelling > 50 mm occurred in 24% of DTPa-primed compared to 5.5% of DTPw-primed children. Large swelling involving the entire upper arm (extending to involve the elbow joint) was reported for up to 1.2% of DTPa-primed subjects, which is consistent with literature reports for other DTPa vaccines. (c) 2005 Elsevier Ltd. All rights reserved.

AB - A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming. Over 99% vaccines developed antibody levels considered to be protective to diphtheria, tetanus and poliovirus, and > 95% mounted a response to acellular pertussis antigens. Rectal temperature > 39.5 degrees C was observed in at most 3.2% of vaccinees. Swelling > 50 mm occurred in 24% of DTPa-primed compared to 5.5% of DTPw-primed children. Large swelling involving the entire upper arm (extending to involve the elbow joint) was reported for up to 1.2% of DTPa-primed subjects, which is consistent with literature reports for other DTPa vaccines. (c) 2005 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.vaccine.2005.12.009

DO - 10.1016/j.vaccine.2005.12.009

M3 - Article

C2 - 16406224

VL - 24

SP - 2440

EP - 2448

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this